Objective: This study aimed to compare choroidal thickness between patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) in complete renal remission to that of patients with SLE without LN. Methods: This was a retrospective case-control study of 23 SLE patients meeting either the American College of Rheumatology or Systemic Lupus International Collaborating Clinics classification criteria and followed at Washington University School of Medicine Rheumatology or Nephrology, and Ophthalmology outpatient clinics. The diagnosis of LN was based on renal pathology, and complete renal remission was defined as proteinuria <500 mg/daily and serum creatinine at baseline. Extra-renal flare status was determined using modified Fortin criteria. Choroidal thickness was measured using spectral-domain optical coherence tomography and read by blinded reviewers. Results: In SLE patients without extra-renal flare, choroidal thickness of LN patients was 281 AE 78 mm compared to 288 AE 70 mm in non-LN SLE patients (p ¼ 0.766) at the fovea. Conclusion: Choroidal thickness was not different in patients with LN in remission compared to non-LN SLE patients in remission. Additional studies are needed to examine choroidal thickness in patients with SLE with active LN. Lupus (2020) 29, 205-209.
Introduction
Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), leading to end-stage renal disease (ESRD) in 30% of patients, and is the most important predictor of SLE mortality. Although survival of patients with LN has improved significantly over the last few decades, the incidence of ESRD from LN, which stabilized in the 1990s, may now be rising, reflecting limits in effective management. 1 One unmet need in LN management is an accurate, noninvasive method to assess renal disease activity and response to therapeutic interventions. While renal biopsy remains the gold standard for initial LN diagnosis, its invasiveness and inherent risks make it impractical to perform frequently and serially. Thus, there is a need to develop an accurate and noninvasive method to evaluate renal disease activity rapidly to inform immunosuppressive therapy.
The choroid and the kidney are ''parallel'' organs with similar vascular design and systemic exposures. Both the choroid and the glomerulus have fenestrated capillaries containing a3-5 type IV collagen and are organized in lobules. 2 Clinical choroidopathy is thought to be due to immune complex deposition, inflammatory cell infiltration, vascular leakage, and subsequent choroidal thickening. 3 Histopathologically, similar findings are observed in proliferative LN with immunoglobulin/complement deposition, active inflammation, and subsequent glomerular injury. 4 While clinical choroidopathy causing visual symptoms occurs infrequently, patients with LN have high rates of subclinical choroidopathy compared to non-LN SLE patients. 5 Hyperfluorescence patterns similar to those seen in other macular diseases on indocyanine green angiography were observed in 100% of patients with LN but in none of the SLE patients without nephritis in one study. 5 Recently, it was shown that LN in remission was associated with increased choroidal thickness compared to non-LN SLE patients in remission. 6 However, the degree of renal remission (partial vs. complete) was not characterized. Partial renal remission (i.e. proteinuria >500 mg/day or creatinine above baseline) in the chronic setting could represent 
Materials and methods

Study population
This was a retrospective analysis of patients followed at the Washington University School of Medicine (WUSM) Lupus Clinic or identified through the WUSM Nephrology Clinic's biopsy database. All patients met SLE classification using either the American College of Rheumatology 7 and/or Systemic Lupus International Collaborating Clinics. 8 Patients with LN had biopsy-proven Renal Pathology Society/International Society of Nephrology class III, IV, or V LN. 9 This study was approved by the WUSM Institutional Review Board.
A chart review was conducted to identify SLE patients who received a comprehensive eye exam including optical coherence tomography (OCT) in the WUSM ophthalmology clinics between January 1, 2012, and December 31, 2018. Patients were excluded if they had conditions that could impact choroidal thickness: spherical equivalent >6 or <-6 diopters, retinal disease, uveitis, pregnancy, or chronic renal disease stage 3 or greater. 10 Spherical equivalent is an estimate of the refractive error of the eye, and was calculated from medical refraction as sphere þ½ cyl in diopter power.
Medical records pertaining to rheumatology and nephrology visits were reviewed before and after OCT imaging for evidence of clinical LN activity and extra-renal flare. Complete renal remission was defined as urine protein <0.5 g/day and return of serum creatinine to previous baseline. Flare was defined by Fortin criteria: (a) new or increased prednisone dose >20 mg/day, (b) new or increased immunosuppression treatment, or (c) hospitalization or death from SLE. 11 Imaging OCT images were collected using a Cirrus SD-OCT platform (Zeiss, Oberkochen, Germany). Choroidal thickness was measured on high-definition images through the fovea using Photoshop CS6 (Adobe, Inc., San Jose, CA) with a method modified from that of Gupta et al. 9 Image quality and measurements were assessed by two trained reviewers masked to group assignment. Choroidal thickness, defined as the linear distance between the retinal pigment epithelial band and the posterior sclerochoroidal junction, 12 was measured at seven locations: 1500, 1000, and 500 mm nasal and temporal to the fovea, and underneath the foveal center (see Figure 1 ). Only OCT images that clearly delineated the interface between the retinal pigment epithelium and posterior sclerochoroidal junction were included in analyses. Choroidal thickness measurement had an intra-rater reliability of 0.982 and an inter-rater reliability of 0.96 after adjudication of measurements with a >15% difference.
Statistical analysis
IBM SPSS Statistics for windows v19 (IBM Corp., Armonk, NY) was used for statistical analyses. For unadjusted comparisons, statistical significance was determined by an independent Student's t-test for continuous and normally distributed outcome variables, and Mann-Whitney U-test for continuous and nonparametric outcome variables. Normality was tested using the Kolmogorov-Smirnov Z test. A linear mixed model was used to adjust for paired measurements, with choroidal thickness at the above-defined points as the outcome of interest. Known predictors of outcome, including age, time of scan (dichotomized into morning and afternoon scans), 13 and spherical equivalent, were entered into models using forced entry. A p-value of <0.05 was considered statistically significant. 
Results
The study cohort consisted of 23 SLE patients: 11 non-LN SLE patients and 12 LN patients. Of the LN patients, 10 (71%) had class III or IV nephritis, or mixed subtype with class III or IV and class V nephritis, and four (29%) had pure class V nephritis.
In the group of patients with LN (Table 1) , all subjects were in complete renal remission, with a median spot protein/creatinine ratio of 0.2 (interquartile range (IQR) 0.1-0.3) and a median serum creatinine of 0.84 (IQR 0.71-1.04). All non-LN SLE patients had a urine spot protein/creatinine ratio of 0.1 and median serum creatinine of 0.83 (IQR 0.62-0.93). There was no difference in choroidal thickness between patients with LN in complete renal remission compared to SLE patients without LN at any of the seven measured locations through the fovea (see Figure 2 and Table 2 ). Thus, in the absence of extra-renal disease activity and renal activity, subjects with LN had equivalent CT choroidal measurements compared to those without LN. Year of onset was not available for one patient. LN: lupus nephritis; SLE: systemic lupus erythematosus; OCT: optical coherence tomography; SD: standard deviation; IQR: interquartile range.
Discussion
SLE is an autoimmune disease that may affect multiple organs, including the kidney. While LN is the most important predictor of mortality, involvement of other organs during lupus flares also results in morbidity. 14 In LN, kidney biopsy has been the gold standard for the diagnosis and prognosis of disease, but frequent repeat biopsies are not often done due to the invasiveness of the procedure. Clinical biomarkers including urine protein and serum creatinine are often used to follow LN activity, but clinical remission may be discordant with histologic remission in 30% of cases. 15 Thus, major unmet needs in the clinical care of SLE patients are noninvasive and accurate methods for assessing LN. This study comprises preliminary work to assess the association between choroidal thickness and LN. We found that LN in complete renal remission was not associated with an increase in choroidal thickness compared to non-LN SLE patients. While Braga et al. observed that the choroid was thicker in LN in remission compared to non-LN SLE patients in remission, 6 the clinical characteristics of the study cohorts are dissimilar. Braga et al. did not define renal and extra-renal inactivity or remission. In addition, our LN group had a lower proportion of class III/IV and higher proportion of class V LN (71% and 29% vs. 93% and 7%, respectively) and included only patients who were in complete renal remission with 24-hour urine protein <500 mg and serum creatinine at baseline. Thus, the findings of these two studies may not be contradictory but rather represent a spectrum of subclinical choroidal changes in different groups of LN patients. Supporting this theory is a case report of a patient with LN and clinical choroidopathy in whom achievement of complete remission led to resolution of both clinical choroidopathy and a reduction in choroidal thickness. 16 The strengths of our study include the biopsy documentation of LN and the examination of only patients who were in complete renal remission and without extra-renal flare. Our main limitations are small the sample size and retrospective design, which precluded using standardized clinical examinations performed synchronously with OCT scanning, and standardized validated instruments to measure lupus activity.
In summary, our findings add to the existing data on the potential association between choroidal thickness and LN. Larger, prospective studies are required to characterize this relationship better and to explore putative mechanisms underlying the variation in choroidal thickness in SLE patients, including the role of immune complex deposition, and endothelial damage. 
